Search Result

Results for "

low density lipoprotein

" in MedChemExpress (MCE) Product Catalog:

By Targets:	LDLR (10) Acyltransferase (1) Akt (2) AMPK (1) Apical Sodium-Dependent Bile Acid Transporter (1) Apoptosis (9) Autophagy (10) Bacterial (4) Biochemical Assay Reagents (2) CETP (2) COX (2) Cytochrome P450 (2) Endogenous Metabolite (7) ERK (3) Fatty Acid Synthase (FASN) (2) Ferroptosis (2) FXR (3) Glucosidase (1) HMG-CoA Reductase (HMGCR) (14) Interleukin Related (1) Keap1-Nrf2 (2) Lipoxygenase (1) LXR (1) MicroRNA (2) Mitophagy (4) NF-κB (3) NO Synthase (1) NOD-like Receptor (NLR) (1) p38 MAPK (3) PCSK9 (14) Phosphatase (1) PKA (2) Potassium Channel (6) PPAR (4) RAR/RXR (1) Reactive Oxygen Species (3) ROR (2) Thyroid Hormone Receptor (1)
By Research Areas:	Cancer (16) Cardiovascular Disease (28) Endocrinology (1) Inflammation/Immunology (11) Metabolic Disease (53) Neurological Disease (5)
Oligonucleotides:	Fillers (1)

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

*Oxidized low* density lipoprotein (mouse)** Mouse ox-LDL	LDLR	Cardiovascular Disease
Oxidized low density lipoprotein (mouse) is an oxidized low density lipoprotein (LDL). Oxidized low density lipoprotein (mouse) induces atherosclerosis (AS) by facilitating endothelial dysfunction and accelerating the VSMCs growth and migration .

Recaticimab SHR-1209	PCSK9 LDLR	Metabolic Disease
Recaticimab (SHR-1209) is an orally active humanized monoclonal antibody targeting PCSK9. Recaticimab binds PCSK9 with high affinity, increases the level of low density lipoprotein receptor on the surface of liver cells, and decreases the level of low density lipoprotein cholesterol in plasma. Recaticimab can be used in the study of hypercholesterolemia and hyperlipidemia .

LDL-IN-2	LDLR	Metabolic Disease
LDL-IN-2 (compound 3) is an antioxidant against copper mediated low-density lipoproteins (LDL) oxidation .

Garlic Extract	Others	Cardiovascular Disease
Garlic Extract is a garlic extract, and its components include: Allicin. Garlic Extract is beneficial to cardiovascular disease and has the potential to reduce the risk of cardiovascular disease. Garlic Extract can effectively reduce total cholesterol, low-density lipoprotein levels and improve high-density lipoprotein levels. .

Phillygenin 2 Publications Verification Phillygenol; Epipinoresinol methyl ether; (+)-Phillygenin	Reactive Oxygen Species	Others
Phillygenin (Phillygenol) is an active ingredient from Forsythia with many medicinal properties, such as antioxidant, reducing blood lipid, inhibition of low density lipoprotein oxidation.

*Oxidized low* density lipoprotein (Human)** Human ox-LDL	NO Synthase NOD-like Receptor (NLR)	Metabolic Disease Inflammation/Immunology
Oxidized low density lipoprotein (Human) (Human ox-LDL) is involved in atherogenesis. Oxidized low density lipoprotein (Human) induces endothelial dysfunction via cytoplasmic adapter protein TRAF3IP2. Oxidized low density lipoprotein (Human) can stimulate the activation of endothelial cells and the production of adhesion molecules, and inhibits eNOS activity and NO production. Oxidized low density lipoprotein (Human) can activate NLRP3 inflammasome in macrophages .

VH4127	LDLR	Metabolic Disease
VH4127 is a cyclic peptide targeting the low density lipoprotein receptor (LDLR) with a K_D of 18 nM for hLDLR. VH4127, bearing non-natural amino acid residues, specifically binds to rodent and human epidermal growth factor (EGF) homology domain of LDLR .

GW 590735 sodium	PPAR	Metabolic Disease
GW 590735 sodium is a potent and selective PPARα agonist with activity in regulating lipid metabolism. GW 590735 significantly increased high-density lipoprotein (HDL) cholesterol, decreased low-density lipoprotein (LDL) and very low-density lipoprotein (VLDL) cholesterol, and significantly reduced triglycerides. The maximum increases in HDL cholesterol for GW 590735 were 37%, 53% and 84%, respectively, compared with bezafibrate, torcetrapib and GW 590735 .

CVI-LM001	PCSK9	Metabolic Disease
CVI-LM001 is an inhibitor PCSK 9. CVI-LM001 inhibits the interaction of PCSK9 with low-density lipoprotein receptor (LDLR), regulates the level of low-density lipoprotein cholesterol (LDL-C) in the blood, and exhibits lipid-lowering efficacy .

S12340	LDLR	Cardiovascular Disease
S12340 is a a inhibitor of the oxidative modification of low-density lipoprotein and shows protective effect on cardiac cells exposed to oxidative stress .

MK-8262	CETP	Cardiovascular Disease Metabolic Disease
MK-8262 is an orally active and potent *cholesteryl ester transfer protein* (CETP) inhibitor with an IC₅₀** of 53 nM and a log D of 5.3. MK-8262, a bistrifluoromethyl analogue, has the potential for coronary heart disease (CHD) correlated high-density lipoprotein (HDL) and low-density lipoprotein (LDL) research .

Stachybotramide	Others	Metabolic Disease
Stachybotramide is a natural fungal metabolite with the property of modulating the activity of cholesteryl ester transfer protein (CETP). Stachybotramide stimulates the transfer of cholesteryl esters (CE) from high-density lipoprotein (HDL) to very-low-density lipoprotein (VLDL) and low-density lipoprotein (LDL), increasing the transfer efficiency by 1.3- to 1.5-fold. Stachybotramide slightly reduced the transfer of cholesteryl esters from LDL and VLDL to HDL at 0.5 mM. The effect of Stachybotramide on the transfer of triglycerides (TG) from HDL was not significant. By these results, Stachybotramide was shown to preferentially stimulate the CETP-mediated transfer of cholesteryl esters from HDL to VLDL and LDL .

3-Chloro-L-tyrosine 3-Chlorotyrosine	Endogenous Metabolite	Others
3-Chloro-L-tyrosine is a specific marker of myeloperoxidase-catalyzed oxidation, and is markedly elevated in low density lipoprotein isolated from human atherosclerotic intima.

Milpocitide	LDLR	Others
Milpocitide is a low-density lipoprotein receptor (human LDL receptor, LDLR), (293-333)-peptide fragment (EGF-like domain 1) .

POVPC	Apoptosis	Cardiovascular Disease
POVPC is an oxidized phospholipid can be found in in oxidatively modified low density lipoprotein (oxLDL). POVPC inhibits VSMC growth in high serum condition. POVPC induces apoptosis in low serum condition .

Gemcabene PD-72953	Others	Metabolic Disease Inflammation/Immunology
Gemcabene (PD-72953), a first-in-class lipid-lowering agent, lowers low-density lipoprotein cholesterol (LDL-C), decreases triglycerides, and raises high-density lipoprotein cholesterol (HDL-C) and lowers pro-inflammatory acute-phase protein, C-reactive protein (CRP), exerting anti-inflammatory activity .

Cholesteryl behenate 1 Publications Verification Cholesteryl docosanoate; Cholesterol behenate	Endogenous Metabolite	Metabolic Disease
Cholesteryl behenate is a cholesterol ester associated with the neutral core of low density lipoprotein Receptor-LDL complexes are taken up by lysosomes and hydrolyzed to release cholesterol from the esters.

Rosmanol	COX	Inflammation/Immunology Cancer
Rosmanol could inhibit the oxidation of low density lipoprotein (LPL) and significantly inhibit lipopolysaccharide induced iNOS and COX-2 expression, with anti-inflammatory effect.

Campestanol	Others	Metabolic Disease
Campestanol is a phytosterol that can be found in plant food. Campestanol lowers serum cholesterol and low-density lipoprotein. Campestanol can be used for the research of metabolic disorders .

Gemcabene calcium PD-72953 calcium	Others	Metabolic Disease Inflammation/Immunology
Gemcabene calcium (PD-72953 calcium), a first-in-class lipid-lowering agent, lowers low-density lipoprotein cholesterol (LDL-C), decreases triglycerides, and raises high-density lipoprotein cholesterol (HDL-C) and lowers pro-inflammatory acute-phase protein, C-reactive protein (CRP), exerting anti-inflammatory activity .

Lipid-lowering agent-1	Others	Others
Lipid-lowering agent-1 is a potent lipid-lowering agent. Lipid-lowering agent-1 has significant pharmacological effects on the inhibition of low-density lipoprotein cholesterol (LDLC) and promotion of high-density lipoprotein cholesterol (HDLC) production. Lipid-lowering agent-1 shows potent hypolipidemic effect in high-fat diet rats .

Acetoacetic acid sodium 3 Publications Verification	Endogenous Metabolite	Metabolic Disease
Acetoacetic acid sodium is a metabolite of non-esterified fatty acids, involved in the development of human diabetes. Acetoacetic acid sodium induces oxidative stress to inhibit the assembly of very low density lipoprotein in bovine hepatocytes .

PCSK9-IN-30	PCSK9	Cardiovascular Disease
PCSK9-IN-30 (Compound 3f) is a PCSK9 inhibitor. PCSK9-IN-30 interacts with a cryptic binding groove of PCSK9, inhibiting the binding of PCSK9 to the low-density lipoprotein receptor (LDLR) (IC₅₀ = 537 nM), restoring the uptake of low-density lipoprotein (LDL) by liver cells, and ultimately reducing plasma cholesterol levels. PCSK9-IN-30 exhibits good bioavailability in mice and can be used for research in the field of cardiovascular diseases .

Orticumab MLDL1278A	LDLR	Inflammation/Immunology
Orticumab (MLDL1278A) is an antibody targeting to oxidized or malondialdehyde-modified lipoprotein (LDL). Orticumab specifically inhibits oxidized **low-density lipoproteins (oxLDL**). Orticumab involves in modulation of autoimmune responses against oxLDL, improves atherosclerosis in animal model. Orticumab also can be used for research of psoriasis improvement .

5-O-Methylembelin	PCSK9	Cardiovascular Disease
5-O-Methylembelin is a natural isocoumarin that inhibits PCSK9, *inducible degrader of the low-density* lipoprotein receptor (IDLR), and sterol regulatory element binding protein 2 (SREBP2)** mRNA expression .

Polydextrose	Biochemical Assay Reagents	Metabolic Disease Cancer
Polydextrose has the effect of lowering cholesterol and plasma lipids, and can effectively reduce low-density lipoprotein cholesterol. Polydextrose significantly reduced plasma and liver cholesterol in gerbils fed with enlarged endogenous cholesterol reservoirs .

PCSK9-IN-13	PCSK9	Cardiovascular Disease Metabolic Disease
PCSK9-IN-13(compound 3f) is a potent PCSK9 inhibitor, which can antagonize low-density lipoprotein (LDL) receptor binding by binding to PCSK9, with an IC₅₀ of 537 nM .

Lysophosphatidylcholines 1 Publications Verification	Interleukin Related p38 MAPK ERK Apoptosis	Inflammation/Immunology
Lysophosphatidylcholines is an orally active lysolipid and a component of oxidized low density lipoprotein (LDL). Lysophosphatidylcholines induces cell injury, the production of IL-1β and apoptosis. Lysophosphatidylcholines has a proactive effect on sepsis .

Rosmanol (Standard)	COX	Inflammation/Immunology Cancer
Rosmanol (Standard) is the analytical standard of Rosmanol. This product is intended for research and analytical applications. Rosmanol could inhibit the oxidation of low density lipoprotein (LPL) and significantly inhibit lipopolysaccharide induced iNOS and COX-2 expression, with anti-inflammatory effect.

Oleic Acid-2,6-diisopropylanilide	Endogenous Metabolite	Metabolic Disease
AcylCoA:cholesterol acyltransferase (ACAT) is an intracellular cholesteryl ester synthase tied closely to the absorption of dietary cholesterol.1 Oleic acid-2,6-diisopropylanilide is an inhibitor of acylCoA:cholesterol acyltransferase with an IC₅₀ of 7 nM.2 When co-administered to rabbits or rats fed a high fat, high cholesterol diet, oleic acid-2,6-diisopropylanilide decreased low density lipoproteins and elevated high density lipoprotein levels when administered at 0.05%.

Imanixil HOE-402(free base)	LDLR	Cardiovascular Disease
Imanixil (HOE-402 free base) is an inducer of the LDL receptor (LDLR). Imanixil (HOE-402 free base) is also a potent cholesterol-lowering compound, which inhibits very low density-lipoprotein (VLDL) production, and consequently attenuates atherosclerosis development .

alpha-CEHC	Others	Others
alpha-CEHC is a water-soluble metabolite of alpha-tocopherol (α-TOH) with potential antioxidant activity. alpha-CEHC slightly inhibits macrophage-induced low-density lipoprotein (LDL) oxidation, and its inhibitory potency is concentration-dependent .

PCSK9-IN-31	PCSK9	Metabolic Disease
PCSK9-IN-31 (Compound WX002) is an orally active PCSK9 inhibitor. PCSK9-IN-31 can lower low-density lipoprotein cholesterol (LDL-C) and total cholesterol (TC) in high cholesterol fed model rats .

PCSK9 modulator-2	PCSK9	Metabolic Disease
PCSK9 modulator-2 (Compound 1) is a potent modulator of PCSK9 with an EC₅₀ value of 202 nM. PCSK9 is a recently validated target for lowering low-density lipoprotein cholesterol (LDL-C). PCSK9 modulator-2 has the potential for the research of hyperlipidemia .

Lapaquistat acetate TAK-475	Others	Metabolic Disease
Lapaquistat acetate (TAK-475) is a squalene synthase inhibitor, blocking the conversion of farnesyl diphosphate (FPP) to squalene in the cholesterol biosynthesis pathway . Lapaquistat acetate is effective at lowering low-density lipoprotein cholesterol, but it might cause liver damage. Lapaquistat acetate is used for hypercholesterolemia and mevalonate kinase deficiency (MKD) research .

(E/Z)-Polydatin (E/Z)-Piceid	Others	Inflammation/Immunology
(E/Z)-Polydatin ((E/Z)-Piceid) is a monocrystalline compound originally isolated from the root and rhizome of Polygonum cuspidatum. (E/Z)-Polydatin has anti-platelet aggregation, anti-oxidative action of low-density lipoprotein (LDL), cardioprotective activity, anti-inflammatory and immune-regulating functions .

PCSK9 modulator-3	PCSK9	Metabolic Disease
PCSK9 modulator-3 (Compound 13) is a potent modulator of PCSK9 with an EC₅₀ value of 2.46 nM. PCSK9 is a recently validated target for lowering low-density lipoprotein cholesterol (LDL-C). PCSK9 modulator-3 has the potential for the research of hyperlipidemia .

PCSK9 modulator-4	PCSK9	Metabolic Disease
PCSK9 modulator-4 (Compound 21) is a potent modulator of PCSK9 with an EC₅₀ value of 0.15 nM. PCSK9 is a recently validated target for lowering low-density lipoprotein cholesterol (LDL-C). PCSK9 modulator-4 has the potential for the research of hyperlipidemia .

3-Chloro-L-tyrosine-13C6	Endogenous Metabolite	Others
3-Chloro-L-tyrosine- ¹³C₆ is the ¹³C labeled 3-Chloro-L-tyrosine[1]. 3-Chloro-L-tyrosine is a specific marker of myeloperoxidase-catalyzed oxidation, and is markedly elevated in low density lipoprotein isolated from human atherosclerotic intima[2].

LDL-IN-4	Acyltransferase	Metabolic Disease
LDL-IN-4 (Compound 2) inhibits human acyl-CoA:cholesterol acyltransferase-1 and -2 activities. LDL-IN-4 inhibits copper-mediated low density lipoprotein (LDL) oxidation, with an IC₅₀ of 3 μM. LDL-IN-4 has anti-atherosclerotic biological activity .

Eprotirome KB2115	Thyroid Hormone Receptor	Metabolic Disease Endocrinology
Eprotirome (KB2115) is a liver-selective thyroid hormone receptor (TR) agonist. KB2115 has modestly higher affinity for TRβ than for TRα. Eprotirome reduces low-density lipoprotein (LDL) cholesterol concentrations. Eprotirome can be used for dyslipidemias and obesity research .

PCSK9 degrader 1	PCSK9	Metabolic Disease
PCSK9 degrader 1 (Compound 16) is a small molecule ligand for proprotein convertase substilisin-like/kexin type 9 (PCSK9) and shows high affinity to PCSK9 with a K_i of 107 nM. PCSK9 degrader 1 can involve in a protein-protein interaction with the low-density lipoprotein (LDL) receptor .

PAz-PC PAzePC; Azelaoyl PC; 1-Palmitoyl-2-Azelaoyl PC	Endogenous Metabolite	Metabolic Disease
Oxidized low-density lipoprotein (oxLDL) particles contain low molecular weight species which are cytotoxic and pro-atherogenic. Many of these substances were isolated and purified from oxLDL and identified as phosphatidylcholine species containing a fragmented, oxidized short-chain fatty acid remnant at the sn-2 position. PAz-PC (Azelaoyl PC) is one of the predominant oxLDL species and may be one of the important structural determinants of oxLDL.

4',5-Dihydroxyflavone	Lipoxygenase Glucosidase	Others
4',5-Dihydroxyflavone is a soybean LOX-1 and yeast α-Glucosidase inhibitor, with an K_i of 102.6 μM for soybean LOX-1 and an IC₅₀ of 66 μM for yeast α-glucosidase. LOX-1 isshort for Lectin-like oxidized low-density lipoprotein receptor-1.

N-Acetyldopamine dimer-2	Reactive Oxygen Species NF-κB	Inflammation/Immunology
N-Acetyldopamine dimer-2 (compound 2) is a N-acetyldopamine dimer that can be isolated from the yellow powder form Periostracum Cicadae with antioxidant and anti-inflammatory activities. N-Acetyldopamine dimer-2 inhibits oxidized low-density lipoprotein (LDL) oxidation, ROS generation, NO production, and NF-κB activity .

PCSK9-IN-15	PCSK9	Metabolic Disease
PCSK9-IN-15 (compound 5) is a potent inhibitor of proprotein convertase subtilisin/kexin 9 (PCSK9, K_D <200 nM). PCSK9 is involved in cholesterol metabolism and regulates levels of low-density lipoprotein cholesterol (LDL-C) in the blood. PCSK9- in -15 can be used to study cholesterol-lowering and dyslipidemia .

Cat. No.	Product Name	Type

HY-NP012

Low density lipoprotein (human) Human LDL	Native Proteins
Low density lipoprotein (human) is one of the five major groups of lipoprotein that carries cholesterol to various tissues such as the adrenal gland, gonads, muscle, and adipose tissue .

HY-NP013

*Oxidized low* density lipoprotein (mouse)** Mouse ox-LDL	Native Proteins
Oxidized low density lipoprotein (mouse) is an oxidized low density lipoprotein (LDL). Oxidized low density lipoprotein (mouse) induces atherosclerosis (AS) by facilitating endothelial dysfunction and accelerating the VSMCs growth and migration .

HY-W134326

Polydextrose	Biochemical Assay Reagents
Polydextrose has the effect of lowering cholesterol and plasma lipids, and can effectively reduce low-density lipoprotein cholesterol. Polydextrose significantly reduced plasma and liver cholesterol in gerbils fed with enlarged endogenous cholesterol reservoirs .

HY-139414

Lysophosphatidylcholines 1 Publications Verification	Cell Assay Reagents
Lysophosphatidylcholines is an orally active lysolipid and a component of oxidized low density lipoprotein (LDL). Lysophosphatidylcholines induces cell injury, the production of IL-1β and apoptosis. Lysophosphatidylcholines has a proactive effect on sepsis .

HY-126726

KOdiA-PC

Drug Delivery

Oxidized low-density lipoprotein (oxLDL) particles contain low molecular weight species that are cytotoxic and proatherogenic. Many of these species were recently isolated and purified from oxLDL and identified as phosphatidylcholine species containing fragmented oxidized short-chain fatty acid residues at the sn-2 position. 1-(Palmitoyl)-2-(5-keto-6-octene-dioyl)phosphatidylcholine or KOdiA-PC is one of the most potent CD36 ligands of the oxLDL species. KOdiA-PC confers CD36 scavenger receptor binding affinity to LDL at a frequency of only 2 to 3 KOdiA-PC molecules/LDL particle and may be one of the more important structural determinants of oxLDL.

HY-NP135

Oxidized low density lipoprotein (Human)

Human ox-LDL

Native Proteins

Oxidized low density lipoprotein (Human) (Human ox-LDL) is involved in atherogenesis. Oxidized low density lipoprotein (Human) induces endothelial dysfunction via cytoplasmic adapter protein TRAF3IP2. Oxidized low density lipoprotein (Human) can stimulate the activation of endothelial cells and the production of adhesion molecules, and inhibits eNOS activity and NO production. Oxidized low density lipoprotein (Human) can activate NLRP3 inflammasome in macrophages .

Cat. No.	Product Name	Target	Research Area

HY-P4073

ANG1005 GRN1005; Paclitaxel trevatide	Peptides	Cancer
ANG1005 (Paclitaxel trevatide) is a brain-penetrating peptide-drug conjugate. ANG1005, a taxane derivative, consists of three paclitaxel (HY-B0015) molecules covalently linked to Angiopep-2, designed to cross the blood-brain and blood-cerebrospinal barriers and to penetrate malignant cells via low density lipoprotein receptor-related protein (LRP1) transport system .

HY-P10697

VH4127	LDLR	Metabolic Disease
VH4127 is a cyclic peptide targeting the low density lipoprotein receptor (LDLR) with a K_D of 18 nM for hLDLR. VH4127, bearing non-natural amino acid residues, specifically binds to rodent and human epidermal growth factor (EGF) homology domain of LDLR .

HY-P10502

L57	Peptides	Others
L57 exhibits high affinity to the low-density lipoprotein receptor-related protein 1 (LRP1) with K_i of 45 nM. L57 exhibits blood-brain barrier (BBB) permeability and plasma stability. L57 can be utilized as the carrier for CNS drug delivery .

HY-P10698

VH-N412	LDLR	Neurological Disease
VH-N412 is a vectorized neuropeptide (NT) with good blood-brain barrier permeability. VH-N412 binds to the low-density lipoprotein receptor (LDLR) and neuropeptide receptor 1 (NTSR-1), and acts as a pharmacological-induced hypothermia (PIH) inducer. VH-N412 exhibits anticonvulsant and neuroprotective effects, and can be used in the study of neurological diseases such as epilepsy.

Cat. No.	Product Name	Target	Research Area

HY-P99822

Recaticimab SHR-1209	PCSK9 LDLR	Metabolic Disease
Recaticimab (SHR-1209) is an orally active humanized monoclonal antibody targeting PCSK9. Recaticimab binds PCSK9 with high affinity, increases the level of low density lipoprotein receptor on the surface of liver cells, and decreases the level of low density lipoprotein cholesterol in plasma. Recaticimab can be used in the study of hypercholesterolemia and hyperlipidemia .

HY-P99793

Orticumab MLDL1278A	LDLR	Inflammation/Immunology
Orticumab (MLDL1278A) is an antibody targeting to oxidized or malondialdehyde-modified lipoprotein (LDL). Orticumab specifically inhibits oxidized **low-density lipoproteins (oxLDL**). Orticumab involves in modulation of autoimmune responses against oxLDL, improves atherosclerosis in animal model. Orticumab also can be used for research of psoriasis improvement .

HY-P9928A

Alirocumab (anti-PCSK9) 1 Publications Verification REGN 727(anti-PCSK9); SAR 236553(anti-PCSK9)	PCSK9	Cardiovascular Disease Cancer
Alirocumab (anti-PCSK9) is a human monoclonal antibody inhibiting proprotein convertase subtilisin/kexin type 9 (PCSK9). Alirocumab specifically binds PCSK9, a down regulator of liver low-density lipoprotein (LDL)-receptors, thereby increasing the ability of the liver to bind LDL-cholesterol (LDL-C) and reducing levels of LDL-C in blood. Alirocumab can be used for the research of hypercholesterolemia .

Species:	Human (10) Mouse (2) Rat (2) Cynomolgus (1)
Tag:	His (11) Avi (1) Fc (4)
Source:	HEK293 (15)

Cat. No.	Compare	Product Name	Species	Source

HY-P70235

	LDLR Protein, Human (HEK293, His) 2 Publications Verification rHulow-density lipoprotein receptor/LDLR, His; low-density lipoprotein Receptor; LDL Receptor; LDLR	Human	HEK293
	LDLR Protein plays a pivotal role in cholesterol homeostasis, binding to LDL and mediating cellular uptake through endocytosis. Clustering into clathrin-coated pits is essential for internalization. In microbial infection, LDLR acts as a receptor for hepatitis C virus in hepatocytes, emphasizing its dual functionality in cholesterol metabolism and the cellular response to viral infections. LDLR Protein, Human (HEK293, His) is the recombinant human-derived LDLR protein, expressed by HEK293 , with C-6*His labeled tag.

HY-P73272

	LDLR Protein, Mouse (HEK293, His) low-density lipoprotein receptor; LDLR; LDL Receptor	Mouse	HEK293
	LDLR Protein crucially binds to LDL, transporting cholesterol through endocytosis. Clustering into clathrin-coated pits initiates internalization. Interactions with DAB2, LDLRAP1, ARRB1, SNX17, and immature PCSK9 contribute to its functional versatility. The NPXY motif interaction is impaired by tyrosine phosphorylation. LDLR Protein, Mouse (HEK293, His) is the recombinant mouse-derived LDLR protein, expressed by HEK293 , with C-His labeled tag. The total length of LDLR Protein, Mouse (HEK293, His) is 769 a.a., with molecular weight of ~98-130 kDa.

HY-P76125

	VLDLR Protein, Human (HEK293, His) Very low-density lipoprotein receptor; VLDL-R	Human	HEK293
	VLDLR protein, a versatile receptor, mediates energy metabolism by binding and transporting VLDL into cells. It interacts with Reelin/RELN, APOE-containing ligands, and clusterin/CLU. Inactive VLDLR forms oligomers with LRP8, but upon ligand binding, it rearranges to transmit the extracellular RELN signal via DAB1 phosphorylation, regulating neuron positioning. VLDLR also acts as a stop signal for migrating neurons and serves as a receptor for Semliki Forest virus during microbial infection. VLDLR Protein, Human (HEK293, His) is the recombinant human-derived VLDLR protein, expressed by HEK293, with C-His labeled tag. The total length of VLDLR Protein, Human (HEK293, His) is 770 a.a., with molecular weight (glycosylation form) of 110-130 kDa.

HY-P76477

	LRP-11 Protein, Human (HEK293, His) low-density lipoprotein receptor-related protein 11; LRP-11	Human	HEK293

HY-P77057

	LDLRAD3 Protein, Human (HEK293, Fc) low-density lipoprotein receptor class A domain-containing protein 3; LRAD3	Human	HEK293
	LDLRAD3 protein significantly affects the processing of amyloid precursor protein (APP), possibly reducing soluble APP-α (sAPP-α) and increasing the production of amyloid P3 peptide. Suggested regulation of ITCH and NEDD4 E3 ligases. LDLRAD3 Protein, Human (HEK293, Fc) is the recombinant human-derived LDLRAD3 protein, expressed by HEK293 , with C-hFc labeled tag.

HY-P77057A

	LDLRAD3 Protein, Human (HEK293, hFc) low-density lipoprotein receptor class A domain-containing protein 3; LRAD3	Human	HEK293
	LDLRAD3 protein significantly affects the processing of amyloid precursor protein (APP), possibly reducing soluble APP-α (sAPP-α) and increasing the production of amyloid P3 peptide. Suggested regulation of ITCH and NEDD4 E3 ligases. LDLRAD3 Protein, Human (HEK293, hFc) is the recombinant human-derived LDLRAD3, expressed by HEK293 , with C-hFc labeled tag. ,

HY-P76476

	LRP-10 Protein, Human (HEK293, His) low-density lipoprotein receptor-related protein 10; LRP-10; MSTP087; SP220	Human	HEK293
	The LRP-10 protein is a possible receptor that may mediate internalization and/or signaling of lipophilic molecules.It is speculated that LRP-10 can promote the uptake of lipoprotein APOE in the liver and may play a role in lipid metabolism and processes related to lipoprotein transport.LRP-10 Protein, Human (HEK293, His) is the recombinant human-derived LRP-10 protein, expressed by HEK293 , with C-His labeled tag.

HY-P72392

	LDLR Protein, Human (Biotinylated, HEK293, Avi-His) low-density lipoprotein Receptor; LDL Receptor; LDLR	Human	HEK293
	LDLR Protein plays a pivotal role in cholesterol homeostasis, binding to LDL and mediating cellular uptake through endocytosis. Clustering into clathrin-coated pits is essential for internalization. In microbial infection, LDLR acts as a receptor for hepatitis C virus in hepatocytes, emphasizing its dual functionality in cholesterol metabolism and the cellular response to viral infections. LDLR Protein, Human (Biotinylated, HEK293, Avi-His) is the recombinant human-derived LDLR protein, expressed by HEK293 , with C-Avi, C-6*His labeled tag.

HY-P73838

	LDLR Protein, Mouse (Biotinylated, A23V, C27G, HEK293, His) low-density lipoprotein receptor; LDLR; LDL Receptor	Mouse	HEK293
	LDLR Protein crucially binds to LDL, transporting cholesterol through endocytosis. Clustering into clathrin-coated pits initiates internalization. Interactions with DAB2, LDLRAP1, ARRB1, SNX17, and immature PCSK9 contribute to its functional versatility. The NPXY motif interaction is impaired by tyrosine phosphorylation. LDLR Protein, Mouse (Biotinylated, A23V, C27G, HEK293, His) is the recombinant mouse-derived LDLR protein, expressed by HEK293 , with C-His labeled tag and A23V, C27G mutation.

HY-P76475

	LRP-10 Protein, Human (HEK293, Fc) low-density lipoprotein receptor-related protein 10; LRP-10; MSTP087; SP220	Human	HEK293
	The LRP-10 protein is a possible receptor that may mediate internalization and/or signaling of lipophilic molecules.It is speculated that LRP-10 can promote the uptake of lipoprotein APOE in the liver and may play a role in lipid metabolism and processes related to lipoprotein transport.LRP-10 Protein, Human (HEK293, Fc) is the recombinant human-derived LRP-10 protein, expressed by HEK293 , with C-hFc labeled tag.

HY-P73835

	LOX-1/OLR1 Protein, Rat (HEK293, His) Oxidized low-density lipoprotein receptor 1; LOX-1; OLR1; CLEC8A	Rat	HEK293
	The LOX-1/OLR1 protein plays an important role as a receptor that recognizes, internalizes, and degrades oxidatively modified low-density lipoprotein (oxLDL), a marker of atherosclerosis, in vascular endothelial cells. OxLDL induces endothelial dysfunction, triggering pro-inflammatory responses, oxidative conditions, and apoptosis. LOX-1/OLR1 Protein, Rat (HEK293, His) is the recombinant rat-derived LOX-1/OLR1 protein, expressed by HEK293 , with N-His labeled tag. The total length of LOX-1/OLR1 Protein, Rat (HEK293, His) is 305 a.a., with molecular weight of 43-47 kDa.

HY-P73836

	LOX-1/OLR1 Protein, Rat (HEK293, Fc) Oxidized low-density lipoprotein receptor 1; LOX-1; OLR1; CLEC8A	Rat	HEK293
	The LOX-1/OLR1 protein plays an important role as a receptor that recognizes, internalizes, and degrades oxidatively modified low-density lipoprotein (oxLDL), a marker of atherosclerosis, in vascular endothelial cells. OxLDL induces endothelial dysfunction, triggering pro-inflammatory responses, oxidative conditions, and apoptosis. LOX-1/OLR1 Protein, Rat (HEK293, Fc) is the recombinant rat-derived LOX-1/OLR1 protein, expressed by HEK293 , with N-hFc labeled tag. The total length of LOX-1/OLR1 Protein, Rat (HEK293, Fc) is 305 a.a., with molecular weight of ~66 & 35 kDa, respectively.

HY-P76474

	LOX-1/OLR1 Protein, Cynomolgus (HEK293, His) Oxidized low-density lipoprotein receptor 1; LOX-1; OLR1; CLEC8A	Cynomolgus	HEK293
	OLR1 is a type II membrane glycoprotein belonging to C-type lectin family with a short N-terminal cytoplasmic tail and a long C-terminal extracellular domain. OLR1 binds ox-LDL, delipidated, and solubilized ox-LDL. LOX-1/OLR1 Protein, Cynomolgus (HEK293, His) is the recombinant cynomolgus-derived LOX-1/OLR1 protein, expressed by HEK293 , with N-His labeled tag. The total length of LOX-1/OLR1 Protein, Cynomolgus (HEK293, His) is 213 a.a., with molecular weight of ~37 KDa.

HY-P70946

	LRP-12 Protein, Human (HEK293, His) low-density lipoprotein Receptor-Related Protein 12; LRP-12; Suppressor of Tumorigenicity 7 Protein; LRP12; ST7	Human	HEK293
	LRP-12, a probable receptor, potentially facilitates the internalization of lipophilic molecules and signal transduction. It may function as a tumor suppressor and interacts with proteins RACK1, ZFYVE9, and NMRK2. LRP-12 Protein, Human (HEK293, His) is the recombinant human-derived LRP-12 protein, expressed by HEK293 , with C-6*His labeled tag.

HY-P71180

	OLR1 Protein, Human (HEK293, His) Oxidized low-density lipoprotein Receptor 1; Ox-LDL Receptor 1; C-Type Lectin Domain Family 8 Member A; Lectin-Like Oxidized LDL Receptor 1; LOX-1; Lectin-Like oxLDL Receptor 1; hLOX-1; Lectin-Type Oxidized LDL Receptor 1; OLR1; CLEC8A; LOX1	Human	HEK293
	The OLR1 protein is a receptor on vascular endothelial cells that plays a key role in the recognition, internalization, and degradation of oxidatively modified low-density lipoprotein (oxLDL). As a marker of atherosclerosis, oxLDL induces activation of vascular endothelial cells, leading to proinflammatory responses, oxidative conditions, and apoptosis. OLR1 Protein, Human (HEK293, His) is the recombinant human-derived OLR1 protein, expressed by HEK293 , with C-6*His labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P81166

	ox-LDL Antibody ox-LDL: LDL (Copper oxidized); Cu2SO4 oxidized low density lipoprotein; oxidized low density lipoprotein; low density lipoprotein; MDA oxidized LDL; MDA oxidized low density lipoprotein. 氧化型低密度脂蛋白；	ELISA, IHC-P, IHC-F, FC, ICC/IF	Human
	ox-LDL Antibody is an unconjugated, approximately 31 kDa, rabbit-derived, anti-ox-LDL polyclonal antibody. ox-LDL Antibody can be used for: ELISA, IHC-P, IHC-F, Flow-Cyt, IF expriments in human, background without labeling.

HY-P83717

	LDLR Antibody (YA3452) LDLR_HUMAN; low-density lipoprotein receptor; LDL receptor; FH; FHC; FHCL1; LDLCQ2; low density lipoprotein receptor	WB, IHC-P	Human, Mouse
	LDLR Antibody is an unconjugated, approximately 92 kDa, rabbit-derived, anti-LDLR monoclonal antibody. LDLR Antibody can be used for: WB, IHC-P expriments in human, mouse background without labeling.

HY-P81172

	LOX 1 Antibody Lectin-type oxidized LDL receptor 1; OLR1; lectin-like low density lipoprotein receptor-1; Oxidized low-density lipoprotein receptor 1; Ox-LDL receptor 1; Lectin-like oxidized LDL receptor 1; Lectin-like oxLDL receptor 1; LOX-1; BLOX1; Contains: Oxidized low-density lipoprotein receptor 1, soluble form A; Oxidized low-density lipoprotein receptor 1, soluble form B; OLR1_HUMAN.	WB, IHC-P, ICC/IF, FC	Human, Rat, Rabbit
	LOX 1 Antibody is an unconjugated, approximately 31 kDa, rabbit-derived, anti-LOX 1 polyclonal antibody. LOX 1 Antibody can be used for: WB, IF-Cell, IHC-P, FC expriments in human, mouse background without labeling.

HY-P82383

	ApoER2 Antibody (YA2128) LRP8; APOER2; low-density lipoprotein receptor-related protein 8; LRP-8; Apolipoprotein E receptor 2	WB, IP	Human, Rat, Hamster
	ApoER2 Antibody (YA2128) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA2128), targeting ApoER2, with a predicted molecular weight of 106 kDa (observed band size: 130,106 kDa). ApoER2 Antibody (YA2128) can be used for WB, IP experiment in human, rat, hamster background.

HY-P83131

	LRP2 Antibody (YA2876) low-density lipoprotein receptor-related protein 2; LRP-2; Glycoprotein 330; gp330; Megalin; LRP2; DBS	WB	Human, Mouse, Rat
	LRP2 Antibody (YA2876) is a biotin-conjugated non-conjugated IgG antibody, targeting LRP2, with a predicted molecular weight of 522 kDa (observed band size: 280 kDa). LRP2 Antibody (YA2876) can be used for WB experiment in human, mouse, rat background.

HY-P82565

	SorLA Antibody (YA2310) SORL1; C11orf32; Sortilin-related receptor; low-density lipoprotein receptor relative with 11 ligand-binding repeats; LDLR relative with 11 ligand-binding repeats; LR11; SorLA-1; Sorting protein-related receptor containing LDLR class A repe	WB, IHC-P	Human, Mouse, Rat
	SorLA Antibody (YA2310) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA2310), targeting SorLA, with a predicted molecular weight of 248 kDa (observed band size: 270 kDa). SorLA Antibody (YA2310) can be used for WB, IHC-P experiment in human, mouse, rat background.